Four Days. Four Companies. A Bigger, Dedicated Stage for Healthcare Innovation During JPM 2027 In San Francisco.

Vista Partners’ sister company, Tribe Public (www.TribePublic.com), is expanding its CEO Presentation & Q&A Luncheon series during the annual J.P. Morgan Healthcare Conference, hosting four corporate-sponsored, RSVP-only events January 11-14, doubling its traditional two-event schedule. Taking place daily from noon to 2 p.m., each luncheon is expected to welcome 50–80 attendees from the dedicated Tribe Public community. One company will take center stage each day, giving its CEO a focused opportunity to share the company’s vision, highlight its latest developments and growth opportunities, and engage directly with attendees through a live Q&A. For participating companies, this expanded series offers a compelling platform to elevate visibility, build relationships, and bring their stories to an engaged audience during a major week for healthcare.

A Global Community. A Collective Voice. Direct Access.

Tribe Public aggregates the voices of consumers and investors to attract management teams from some of the world’s most interesting and groundbreaking companies to its corporate-sponsored, RSVP-only CEO presentations, Q&A luncheons, dinners, speaking engagements, and webinars. This growing community now spans 31 countries and is accessed via its ongoing Tribe Public CEO Presentation and Q&A Webinar based event series. Tribe Public also hosts luncheon, dinner, and speaking engagement events across 41 Tribe Event Venues in the United States. Members regularly learn alongside one another and engage directly with company leadership and experts. The Tribe Public audience includes portfolio managers from large and small funds, registered investment advisors, family offices, accredited investors, business owners, retail traders, brokers, sell-side analysts, entrepreneurs, and members of the media. This diverse community brings thoughtful questions and a broad range of perspectives to every conversation.

Capital-Markets Expertise. An Integrated Communications Platform.

Vista Partners LLC is a California-registered investment advisor with capital-markets and strategic-advisory capabilities. Its focus complements the opportunity for companies to communicate their vision, articulate their growth strategies, and build meaningful relationships with the investment community. Vista is led by its Managing Member, John F. Heerdink, Jr, an advisor, investor and entrepreneur, who has advised public and private companies across all sectors with an emphasis on biotechnology, healthcare, technology & natural resource companies. In addition, Mr. Heerdink has worked with companies seeking a listing on public exchanges via IPO, reverse merger and assisted foreign issuers seeking a listing on a U.S. exchange. Mr. Heerdink has assisted companies to raise debt and equity capital for growth, consummated mergers and acquisitions, and performed all other matters dealing with investor relations, business development, & marketing. He maintains an extensive relationship base in the investment community, lending industry, investment banking industry & a worldwide investor network. Learn more about Vista Partners: www.vistapglobal.com/about-vista-partners/.

Tribe Public LLC is an integrated media, communications, and investor-event platform that supports live experiences, digital events, original content development, social distribution, and targeted outreach. These capabilities create opportunities to extend company storytelling beyond a single presentation and support continued audience engagement. Learn more about Tribe Public: www.TribePublic.com.

With an expanded four-day luncheon series and a growing global community, Tribe Public is creating more opportunities for healthcare leaders to tell their stories, and for investors and consumers to hear directly from the people shaping what comes next. if you would care to join these upcoming events, then please join the Tribe by registering at www.TribePublic.com and or send a message to Events@TribePublic.com. If you are a company that would like to learn more and/or to be considered to be a presenter during the J.P Morgan Healthcare Week in San Francisco or otherwise across the U.S., then please send a request to Research@TribePublic.com.

JPM 2026 Tribe Presenters Prospered

Alpha Cognition Inc. (NASDAQ: ACOG) has moved meaningfully beyond the familiar small-cap biotech ritual of promising future potential. Since CEO Michael McFadden’s January 15, 2026 Tribe Public CEO luncheon presentation during the J.P. Morgan Healthcare Conference week in San Francisco, the company has paired its Alzheimer’s commercial launch with accelerating prescription metrics, a growing clinical-evidence program and strengthened European intellectual-property protection. The market has noticed. ACOG closed at $5.82 on January 15, 2026 and $9.52 on September 4, 2026, an increase of approximately 63.6%. That compares with a 46.5% year-to-date return reported by Yahoo Finance as of September 4. At the Tribe Public CEO luncheon in San Francisco, Alpha Cognition’s case centered on the commercial opportunity for ZUNVEYL®, its FDA-approved oral treatment for mild-to-moderate Alzheimer’s disease, and the possibility that differentiated tolerability could matter in a market where caregivers, clinicians and patients have little appetite for avoidable complexity. Since then, the company has produced the sort of operating evidence investors generally prefer to PowerPoint optimism: revenue, prescription growth, repeat physician engagement and rising long-term-care penetration. Small-cap biotech shares are rarely accused of moving in a straight line, but ACOG’s direction has become increasingly difficult to mistake.

Since Founder and CEO James Heliwell M.D. presented a their own Tribe Public CEO luncheon event during the J.P. Morgan Healthcare Conference week in January 2026, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has prospered and the stock has establish a new 52-week high of $9.32. Recently, Eupraxia added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose patients after a single administration, arrive as analysts publish price targets ranging from $11 to $25 and investors focus on a pivotal near-term event: interim data from the randomized, placebo-controlled RESOLVE Phase 2b study expected in December 2026.